Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
    31.
    发明授权
    Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion 失效
    吡咯(1,2-a)吡嗪作为胃酸分泌抑制剂

    公开(公告)号:US5041442A

    公开(公告)日:1991-08-20

    申请号:US560528

    申请日:1990-07-31

    IPC分类号: C07D497/04

    CPC分类号: C07D497/04 Y10S514/927

    摘要: This invention is directed to compounds of formula (I): ##STR1## wherein R.sup.1 is thiocyano, --CH.sub.2 CN, --NH.sub.2, --NHR.sup.5, or --CH.sub.2 OR.sup.5 where R.sup.5 is lower alkyl;R.sup.2 is hydrogen, halo, lower alkyl, or lower alkylthio;R.sup.3 is hydrogen, halo, lower alkyl, lower alkylthio, or thiocyano;R.sup.4 is hydrogen, halo, lower alkyl, lower alkoxy, lower alkylthio, or lower alkylsulfonyl; andY is --O--CH.sub.2 --, --S--CH.sub.2 --, --CH.dbd.CH--, or --(CH.sub.2).sub.n -- where n is 0, 1, 2, 3 or 4;or a pharmaceutically acceptable salt thereof. These compounds are useful in treating mammals having disease-states characterized by excessive gastric acid secretion.

    摘要翻译: 本发明涉及式(I)的化合物:其中R 1是硫氰基,-CH 2 CN,-NH 2,-NHR 5或-CH 2 OR 5,其中R 5是低级烷基; R2是氢,卤素,低级烷基或低级烷硫基; R3是氢,卤素,低级烷基,低级烷硫基或硫氰基; R4是氢,卤素,低级烷基,低级烷氧基,低级烷硫基或低级烷基磺酰基; 并且Y是-O-CH 2 - , - S-CH 2 - , - CH = CH-或 - (CH 2)n - ,其中n是0,1,2,3或4; 或其药学上可接受的盐。 这些化合物可用于治疗以过度胃酸分泌为特征的疾病状态的哺乳动物。

    5-Benzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids and
pharmaceutical use thereof
    35.
    发明授权
    5-Benzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids and pharmaceutical use thereof 失效
    5-苯甲酰基-1,2-二氢-3H-吡咯并[1,2-a]吡咯-1-羧酸及其药物用途

    公开(公告)号:US4505927A

    公开(公告)日:1985-03-19

    申请号:US339813

    申请日:1982-01-15

    CPC分类号: C07D487/04 C07D207/34

    摘要: 5-benzoyl-7-halo-1,2-dihydro-3H-pyrrolo[1,2-a]-pyrrole-1-carboxylic acids, represented by the formula ##STR1## and the pharmaceutically acceptable non-toxic esters and salts thereof, wherein:R is hydrogen or lower alkyl;X is hydrogen, lower alkyl, lower alkoxyl, lower alkoxycarbonyl, carboxyl, lower alkylcarbonyl, sulfonic acid, sulfonic acid alkyl ester, fluoro, chloro, or bromo; and Y is chloro or bromo, which are novel, and 5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids which are represented by the formula ##STR2## wherein X and R are as above defined except that X cannot be chloro or bromo, are prepared by decarboxylation of the corresponding 1,1 dicarboxylates. Intermediates in said preparation are also disclosed.

    摘要翻译: 由式(VII)表示的5-苯甲酰基-7-卤代-1,2-二氢-3H-吡咯并[1,2-a] - 吡咯-1-羧酸和药学上可接受的无毒酯 及其盐,其中:R为氢或低级烷基; X是氢,低级烷基,低级烷氧基,低级烷氧基羰基,羧基,低级烷基羰基,磺酸,磺酸烷基酯,氟,氯或溴; 和Y是氯或溴,它们是新的,由式(VI)表示的5-苯甲酰基-1,2-二氢-3H-吡咯并[1,2-a]吡咯-1-羧酸, 其中X和R如上所定义,除了X不能是氯或溴以外,是通过相应的1,1-二羧酸脱羧制备的。 还公开了所述制备中的中间体。

    Imidazolidinone prostaglandins, compositions and use
    36.
    发明授权
    Imidazolidinone prostaglandins, compositions and use 失效
    咪唑啉酮前列腺素,成分及用途

    公开(公告)号:US4496577A

    公开(公告)日:1985-01-29

    申请号:US539197

    申请日:1983-10-05

    摘要: This invention relates to novel imidazolidinone prostaglandin compounds of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.1 and R.sup.2 are independently hydrogen or alkyl of 1 to 4 carbons; R.sup.3 is hydrogen or methyl; and R4 is --(CH.sub.2).sub.n CH.sub.3 wherein n is 3-7, cycloalkyl of 5-7 carbons, a substituent of the formula ##STR2## wherein R.sup.5 is hydrogen, alkyl of 1 to 4 carbons, alkoxy of 1 to 4 carbons, halo or trifluoromethyl. These compounds are inhibitors of blood platelet aggregation.

    摘要翻译: 本发明涉及式(I)的新型咪唑啉酮前列腺素化合物及其药学上可接受的盐,其中R 1和R 2独立地是氢或1至4个碳的烷基; R3是氢或甲基; 并且R 4是 - (CH 2)n CH 3,其中n是3-7,5-7个碳的环烷基,式的取代基,其中R5是氢,1至4个碳的烷基,1个烷氧基, 至4个碳,卤素或三氟甲基。 这些化合物是血小板聚集的抑制剂。

    5-Benzoyl-7-halo-1,2-dihydro-3H-pyrrolo-[1,2-a]pyrrole-1,1-dicarboxylic
acids and esters thereof
    37.
    发明授权
    5-Benzoyl-7-halo-1,2-dihydro-3H-pyrrolo-[1,2-a]pyrrole-1,1-dicarboxylic acids and esters thereof 失效
    5-苯甲酰基-7-卤代-1,2-二氢-3H-吡咯并[1,2-a]吡咯-1,1-二羧酸及其酯

    公开(公告)号:US4456759A

    公开(公告)日:1984-06-26

    申请号:US387562

    申请日:1982-06-11

    CPC分类号: C07D487/04 C07D207/34

    摘要: 5-benzoyl-7-halo-1,2-dihydro-3H-pyrrolo[1,2-a]-pyrrole-1-carboxylic acids, represented by the formula ##STR1## and the pharmaceutically acceptable non-toxic esters and salts thereof, wherein:R is hydrogen or lower alkyl;X is hydrogen, lower alkyl, lower alkoxyl, lower alkoxycarbonyl, carboxyl, lower alkylcarbonyl, sulfonic acid, sulfonic acid alkyl ester, fluoro, chloro, or bromo; and Y is chloro or bromo, which are novel, and 5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids which are represented by the formula ##STR2## wherein X and R are as above defined except that X cannot be chloro or bromo, are prepared by decarboxylation of the corresponding 1,1 dicarboxylates. Intermediates in said preparation are also disclosed.

    摘要翻译: 由式(VII)表示的5-苯甲酰基-7-卤代-1,2-二氢-3H-吡咯并[1,2-a] - 吡咯-1-羧酸和药学上可接受的无毒酯 及其盐,其中:R为氢或低级烷基; X是氢,低级烷基,低级烷氧基,低级烷氧基羰基,羧基,低级烷基羰基,磺酸,磺酸烷基酯,氟,氯或溴; 和Y是氯或溴,它们是新的,由式(VI)表示的5-苯甲酰基-1,2-二氢-3H-吡咯并[1,2-a]吡咯-1-羧酸, 其中X和R如上所定义,除了X不能是氯或溴以外,是通过相应的1,1-二羧酸脱羧制备的。 还公开了所述制备中的中间体。

    3-Substituted-5,6,7,8-tetrahydropyrrolo[1,2-a]-pyridine-and
6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]-azepine carboxylic acid
derivatives useful as blood platelet aggregation inhibitors
    38.
    发明授权
    3-Substituted-5,6,7,8-tetrahydropyrrolo[1,2-a]-pyridine-and 6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]-azepine carboxylic acid derivatives useful as blood platelet aggregation inhibitors 失效
    3-取代的5,6,7,8-四氢吡咯并[1,2-a] - 吡啶和6,7,8,9-四氢-5H-吡咯并[1,2-a] - 吖庚因羧酸衍生物有用 作为血小板聚集抑制剂

    公开(公告)号:US4410534A

    公开(公告)日:1983-10-18

    申请号:US243322

    申请日:1981-03-13

    CPC分类号: C07D471/04 C07D487/04

    摘要: Novel 3-substituted-5,6,7,8-tetrahydropyrrolo[1,2-a]pyridine-8-carboxylic acid and 3-substituted-6,7,8,9-tetrahydro[1,2-a]azepine-9-carboxylic acid compounds represented by the formula ##STR1## and the pharmaceutically acceptable, non-toxic esters and salts thereof, wherein R is hydrogen or a lower alkyl group containing from 1 to 4 carbon atoms, n is the integer selected from the integers 1 or 2 and Ar is a 6- or 5-member ring. These compounds are useful as anti-inflammatory, analgesic and antipyretic agents, platelet aggregation inhibitors, and as smooth muscle relaxants.

    摘要翻译: 新的3-取代-5,6,7,8-四氢吡咯并[1,2-a]吡啶-8-羧酸和3-取代-6,7,8,9-四氢[1,2-a]吖庚因 - 由式表示的9-羧酸化合物及其药学上可接受的无毒酯及其盐,其中R是氢或含有1至4个碳原子的低级烷基,n是选自整数的整数 1或2,Ar是6-或5-元环。 这些化合物可用作抗炎,镇痛和解热剂,血小板聚集抑制剂和平滑肌松弛剂。

    Oxazolidin-2-one prostaglandin compounds
    39.
    发明授权
    Oxazolidin-2-one prostaglandin compounds 失效
    恶唑烷-2-酮前列腺素化合物

    公开(公告)号:US4410526A

    公开(公告)日:1983-10-18

    申请号:US323152

    申请日:1981-11-20

    摘要: Compounds of the formula: ##STR1## and the pharmaceutically acceptable, non-toxic salts and esters (alkyl, 1-6C) thereof, wherein:X is O or S;R.sup.1 is selected from the group consisting of:(a) alkyl or cycloalkyl of 3-8 carbons, ##STR2## R.sup.2 is hydrogen or methyl; exhibit prostaglandin-like activity and are, thus, useful as platelet aggregation inhibitors.

    摘要翻译: 式(I)化合物及其药学上可接受的无毒盐和酯(烷基,1-6C),其中:X是O或S; R1选自:(a)3-8个碳原子的烷基或环烷基,(b) CH2,Y是低级烷基(1-4C),低级烷氧基(1-4C),卤素, 或CF3,和(c)本文定义的 并且R 2是氢或甲基; 表现出前列腺素样活性,因此可用作血小板聚集抑制剂。